News

Despite the challenges of studying the condition, researchers showed that galcanezumab significantly reduced weekly cluster headache attacks compared to placebo.

The investigational new drug application allows the initiation of phase 1/2 clinical trial to assess the safety of BIVV003 in adults.

Agilis Biotherapeutics, Inc. has announced that the company's gene therapy for AADC deficiency results in de novo dopamine production and supports durable Improvement in major motor milestones.

Review finds PrEP can prevent HIV when those at-risk have access, and are adherent to the treatment.

New data being presented at ASGCT detail patients (1.67 to 8.42 years of age) enrolled in a study evaluating the investigational gene therapy treatment, AGIL-AADC.

The researchers hope they will be able to use this template as a drug delivery solution for a variety of eye diseases.

One inhalation product can be effective as a single maintenance and reliever therapy for asthma.

Data is released from a pilot study of X4P-001-IO in combination with nivolumab in patients with clear cell renal cell carcinoma (ccRCC) who are non-responsive to the anti-PD-1 checkpoint inhibitor nivolumab alone.

Medic Vision's iQMR reported 30% reduced brain exam scan time without adverse effects to image quality.

FDA grants orphan drug designation to Sarconeos for Duchenne muscular dystrophy (DMD).

This is the first agent indicated for uninfected adolescents at risk of acquiring HIV.

Positive results yield from a phase 2 tudy of bertilimumab in patients with moderate-to-extensive bullous pemphigoid (BP).

FDA approves Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection.

The approval is backed by evidence from extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data.

The first patient has been dosed in aphase 1/2 study (BMN 270-203) evaluating the investigational gene therapy, valoctocogene roxaparvovec, in severe hemophilia A patients with pre-existing AAV5 antibodies.

On average, shorter gaps in care were not detrimental to patient viral load status, though certain subgroups of patients may benefit from more frequent viral load monitoring.

AstraZeneca announced that the first of its 2 phase 3 trials of benralizumab for severe COPD failed to meet its primary efficacy endpoint.

The practice has only reached a handful of states in 25 years of proposal. What drives the arguments for and against it?

Researchers found that even high-performing hospitals can reduce over-utilization in bronchiolitis using novel de-implementation strategies.

The system is designed for the 3D visualization of bone detail in the lower extremities while the patient remains standing so the anatomy can be assessed while in load bearing positions.

Susan Weisman, a light chain (AL) amyloidosis caregiver for her husband since 2009, touches on a few of her husband's treatments in an approximate timeline.

FDA Approves SC Formulation of Tocilizumab for Polyarticular Juvenile Idiopathic Arthritis (PJIA).

The Spectrum IQ system is designed to integrate with bi-directional EMRs and incorporates the First Databank evidence-based library of IV medications.

Phase 2 clinical study suggests L1-79 has the potential to address an unmet medical need for the treatment of the core symptoms of autism spectrum disorder.

Actemra offers an alternative delivery option to physicians and parents of children 2 years or older to treat PJIA.

The effectiveness of this nutritional prophylactic supplement is determined by genetic variation, making genotype group identification an important factor.

Roche's cobas test systems will now be able to screen multiple individual blood or plasma donations that have been pooled together.

Physicians who received non-research opioid-related payments from the pharmaceutical industry in 2014 had 9.3% more opioid claims in 2015 than physicians who did not.

LogicBio Therapeutics Inc will present data regarding gene editing technologies in hemophilia B and Methylmalonic Acidemia (MMA) at the annual meeting of the ASGCT in Chicago.

Approval provides pediatric epilepsy patients a treatment option to be administered at a therapeutic dose from day 1/